SUBLOCADE forms a solid mass upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo-embolic events, including life threatening pulmonary emboli, if administered ...

On January 8, 2026, Indivior issued full-year 2026 financial guidance, projecting total net revenue between $1.125 billion and $1.195 billion, with SUBLOCADE net revenue expected at $905 million to ...

RICHMOND, Va., May 1, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the publication of a study "Monthly Buprenorphine Depot Injection (SUBLOCADE) for Opioid Use Disorder During ...

SLOUGH, England and RICHMOND, Va., April 16, 2020 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced the publication of long-term safety data for SUBLOCADE® (buprenorphine extended-release) ...

RICHMOND, Va., Oct. 15, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) this week published compelling results from a multicenter, open-label clinical trial published in JAMA Network Open. Two ...

Shares of Indivior (NASDAQ:INDV) dropped on Thursday after the dual-listed U.S. drugmaker lowered its fiscal 2024 guidance for the second time in roughly three months, citing sales headwinds related ...

SUBLOCADE Year-over-Year Growth: Expected to show 17% growth at the midpoint for fiscal year 2024. SUBLOCADE Net Revenue Forecast: Revised guidance due to increased competition and market dynamics.

(RTTNews) - Indivior PLC (INDV, INDV.L), a specialty pharmaceutical company, announced Wednesday that the U.S. Food and Drug Administration has informed that the final review of the SUBLOCADE ...

If approved by the FDA, label would expand to include alternative injection sites in the thigh, buttock and back of the arm for induction and maintenance as well as rapid induction one hour after a ...

Indivior PLC (NASDAQ:INDV) shares are trading lower after the company reported preliminary third-quarter revenue results and cut its FY24 net revenue guidance below estimates. The company expects ...

Bicycle Health, a provider of telemedicine treatment for opioid use disorder, announced that it will make prescriptions for buprenorphine extended release injections (known as Sublocade) available to ...

RICHMOND, Va. and SLOUGH, England, Nov. 30, 2017 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that the U.S. Food and Drug Administration (FDA) has approved SUBLOCADE TM (buprenorphine ...